Home › Compare › MIXIF vs ABBV
MIXIF yields 3.20% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, MIXIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MIXIF + ABBV for your $10,000?
mixi, Inc. engages in the entertainment and lifestyle businesses in Japan. It offers Monster Strike, Kotodaman, and Monster Strike Stadium gaming applications; TIPSTAR, a freemium online betting app; Chariloto, a keirin and auto race betting ticket sales site; Chiba Jets Funabashi; netkeiba.com, a national horse racing resource; and Weekly Baseball Online, a baseball information site. The company also provides FamilyAlbum, a family photo and video sharing app; minimo, a salon artist booking app; mixi, a social networking service that offers space for friendly communication; KARASTA, a karaoke video community; Find Job!, a job recruitment info site for the IT and web industries; and OKURU, a photo gift service. It also provides employment opportunities for people with disabilities; operates XFLAG stores that offer merchandise from game; organizes events; and produces and sells various goods, as well as manages professional sports team, and businesses related to publicly operated competitions and other services. Mixi Inc. offers social networking services that focuses on digital entertainment business, sports business, and lifestyle business. It allows users to connect with their friends. The company was formerly known as eMecury Co., Ltd. and changed its name to mixi, Inc. in February 2006. mixi, Inc. was founded in 1999 and is headquartered in Tokyo, Japan.
Full MIXIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.